OKYO | OKYO Pharma Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.0400 - 1.1000
52 Week Range	0.8080 - 2.1200
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	58,929
Average Volume	192,412
Shares Outstanding	33,886,314
Market Cap	35,580,630
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-05-17

Valuation
Profitability
Growth
Health
P/E Ratio	-1.84
Forward P/E Ratio	N/A
EPS	-0.57
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	UK
Website	OKYO

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO's peers: CADL, KZIA, STSSW, BNOEF, ANEB, CINGW, UNCY, QNRX, CDIO, VRAX, PXMD, SNTI, ZIVO, CVKD, FHTX, CMND, HILS, COEP, MGTA, GDTC

*Chart delayed

Analyzing fundamentals for OKYO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see OKYO Fundamentals page.

Watching at OKYO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on OKYO Technicals page.